| Christopher Paladino, DPM | |
|
28089 Vanderbilt Dr, #104, Bonita Springs, FL 34134-7521 | |
| (239) 498-1176 | |
| (239) 498-5877 |
| Full Name | Christopher Paladino |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 32 Years |
| Location | 28089 Vanderbilt Dr, Bonita Springs, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689674178 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | PO0002435 (Florida) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | PO0002435 (Florida) | Primary |
| Provider Name | Foot & Ankle Care Center Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1962499285 PECOS PAC ID: 4880763960 Enrollment ID: O20080515000071 |
News Archive
"Our findings confirm that patient-specific alerts using faxes to physicians are not effective at improving patient adherence to antidepressant therapy in the absence of other complementary, coordinated interventions," said Bambauer.
"Since 1970, campaigns against smoking seem to have been largely successful, but the message has not been able to reach the youngest ages," says professor Cecilie Svanes at Centre for International Health at The University of Bergen.
As the health care debate intensifies, divisions among lawmakers, competing lobbies and interest groups are increasingly tense.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
A revolutionary compact 3D colour wrist scanner invented by a University of Otago, Christchurch professor will soon be tested in a large scale international clinical trial. This development follows a promising pilot study with New Zealand orthopaedic patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Paladino, DPM 28089 Vanderbilt Drive, #104, Bonita Springs, FL 34134-7521 Ph: (239) 498-1176 | Christopher Paladino, DPM 28089 Vanderbilt Dr, #104, Bonita Springs, FL 34134-7521 Ph: (239) 498-1176 |
News Archive
"Our findings confirm that patient-specific alerts using faxes to physicians are not effective at improving patient adherence to antidepressant therapy in the absence of other complementary, coordinated interventions," said Bambauer.
"Since 1970, campaigns against smoking seem to have been largely successful, but the message has not been able to reach the youngest ages," says professor Cecilie Svanes at Centre for International Health at The University of Bergen.
As the health care debate intensifies, divisions among lawmakers, competing lobbies and interest groups are increasingly tense.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
A revolutionary compact 3D colour wrist scanner invented by a University of Otago, Christchurch professor will soon be tested in a large scale international clinical trial. This development follows a promising pilot study with New Zealand orthopaedic patients.
› Verified 2 days ago
Harry Cotler Inc. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 23421 Walden Center Dr., Ste. 100, Bonita Springs, FL 34134 Phone: 239-444-0700 Fax: 239-444-0900 | |
Gulfcoast Foot And Ankle Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3501 Health Center Blvd, Suite 2150, Bonita Springs, FL 34135 Phone: 239-949-3399 Fax: 239-949-6553 | |
Joint Replacement Institute Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3501 Health Center Blvd, Suite 2180, Bonita Springs, FL 34135 Phone: 239-676-2663 Fax: 239-676-2655 | |
Sunshine State Podiatry Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 24830 Burnt Pine Dr Ste 3, Bonita Springs, FL 34134 Phone: 239-703-9301 |